Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
We have demonstrated that histone deacetylase inhibitors (HDACi) can reinstate immune reactivity in colorectal cancer cells by upregulation of elements of the machinery of immune presentation, including MHC class1. We went on to show that the combination of an HDACi with an immune checkpoint inhibitor delivered synergistic anticancer effects in a syngeneic colorectal cancer (CRC) mouse model. We have performed a clinical trial to test this hypothesis in patients with advanced, refractory CRC with positive results. We have adapted our AI/digital pathology programme to develop a biomarker to select CRC patients who are more likely to benefit from this combination immunotherapy and plan to incorporate this into a prospective clinical trial.
